The sale of Scientific Beta redirects resources toward securities, derivatives, and market data.
Singapore Exchange (SGX) Group has divested its wholly owned subsidiary Scientific Beta as it reallocates capital to businesses it considers critical to its long-term growth strategy.
The exchange operator said in a media release that the sale reflects its active portfolio management approach, allowing it to redirect resources to capabilities that strengthen its multi-asset franchise.
SGX said it will focus future investments on its securities, derivatives and data businesses while sharpening its strategic priorities.
The transaction also positions Scientific Beta for the next phase of growth under its new owner, STOXX Limited.
SGX said the acquisition will enable the index provider to expand its research capabilities and global reach.
Despite the sale, SGX will retain its global multi-asset iEdge platform and continue to develop its index business as part of its broader multi-asset offering.
Ng Yao Loong, head of global financial markets at SGX Group, said the divestment enables the company to focus on areas with long-term growth potential.
“This divestiture allows SGX to focus on areas where we see the strongest opportunities to make an impact for our clients, partners and shareholders and further strengthen our multi-asset offering,” Ng said.
The divestment comes after SGX takes full ownership of Scientific Beta in 2025, following its initial purchase of a 93% stake in 2020 for $274.76 million (€186 million).
In its first half fiscal 2026 results, the exchange operator cited recent financial poor performance and said the unit posted a net loss of about $15 million, including goodwill impairment.
SGX did not disclose financial terms of the transaction.
($1 = €0.68)